Related Experiment Video
Updated: Aug 6, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 regulates the effects of DAPT on Rac1 activation and migration of non-small-cell lung cancer cells
1Department of Physiology, Xuzhou Medical University, No. 209 Tongshan Road, Xuzhou, Jiangsu, 221004, China.
Abstract:
The use of γ-secretase inhibitors to inhibit the activation of Notch receptors can effectively inhibit the malignant process of tumors. Here, we demonstrate that p53 can modulate the effect of DAPT (a γ-secretase inhibitor) on the activation of small GTPase Rac1, thereby affecting cell migration of non-small-cell lung cancer H1299 and A549 cells. After treatment with 20 μM DAPT, activation of Rac1 was increased in H1299 cells but not in A549 cells. We further found that the migration ability of H1299 cells was increased, whereas that of A549 cells was reduced. The effect of DAPT on H1299 migration was repressed by Rac1-T17N, a dominant inactivated mutant of Rac1. H1299 is a p53-deficient cell line. When p53 protein was overexpressed in H1299 cells with a pEGFP-p53 plasmid, DAPT treatment no longer activated Rac1 and increased migration ability. Moreover, DAPT promoted the migration of H1299 cells by increasing the activity of Rac1 through the non-canonical Notch pathway. Taken together, these results indicate that the expression of p53 protein in lung cancer cells regulates the effect of DAPT on cell migration by modulating the activation of Rac1, suggesting that p53 may affect the therapeutic effects of Notch inhibitors in lung cancer patients.
Insights
p53 protein regulates the impact of γ-secretase inhibitors on non-small-cell lung cancer cell migration by modulating Rac1 activation. This suggests p53 influences Notch inhibitor therapy effectiveness in lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Notch receptor signaling is crucial in tumor progression.
- γ-secretase inhibitors (GSIs) target Notch activation to impede cancer growth.
- The role of p53 in modulating GSI efficacy remains unclear.
Purpose of the Study:
- To investigate how p53 influences the effect of DAPT, a GSI, on non-small-cell lung cancer (NSCLC) cell migration.
- To elucidate the mechanism involving Rac1 activation and the Notch pathway.
Main Methods:
- Treatment of NSCLC cell lines (H1299, A549) with DAPT.
- Assessment of Rac1 activation and cell migration.
- Overexpression of p53 in p53-deficient H1299 cells.
- Utilizing a dominant-negative Rac1 mutant (Rac1-T17N).
Main Results:
- DAPT increased Rac1 activation and migration in p53-deficient H1299 cells, but not in A549 cells.
- Overexpressing p53 in H1299 cells blocked DAPT-induced Rac1 activation and migration.
- DAPT's pro-migratory effect in H1299 cells was dependent on Rac1 activity via the non-canonical Notch pathway.
Conclusions:
- p53 expression status modulates DAPT's effect on NSCLC cell migration by regulating Rac1 activation.
- p53 influences the therapeutic potential of Notch inhibitors in lung cancer.
- Targeting p53 or Rac1 may enhance GSI treatment strategies for lung cancer.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity

